Novartis Lamisil One-Week Cure Ad Claims Substantiated - NAD
This article was originally published in The Tan Sheet
Novartis Consumer Health's Lamisil AT "cures with just one week's use" advertising claim for the treatment of athlete's foot is not likely to mislead consumers, the National Advertising Division of the Council of Better Business Bureaus determined.
You may also be interested in...
Schering-Plough's Lotrimin Ultra will launch nationwide in the first quarter of 2002, marking the third generation of OTC athlete's foot antifungals to bear the Lotrimin name
The "triple-strength" of Desenex Max compared to other available OTC athlete's foot remedies is emphasized in promotions accompanying the launch of Novartis' new terbinafine hydrochloride 1% cream.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC